John Renger's most recent trade in Cerevel Therapeutics Holdings Inc was a trade of 5,020 Common Stock done . Disclosure was reported to the exchange on Feb. 6, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cerevel Therapeutics Holdings | Renger John | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 5,020 | 8,531 | - | - | Common Stock | |
| Cerevel Therapeutics Holdings | Renger John | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 5,020 | 15,061 | - | - | Restricted Stock Units | |
| Cerevel Therapeutics Holdings | Renger John | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.54 per share. | 06 Feb 2024 | 2,161 | 6,370 | - | 41.5 | 89,777 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 87,573 | 87,573 | - | - | Restricted Stock Units | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 79,022 | 79,022 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 20,081 | 20,081 | - | - | Restricted Stock Units | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 01 Nov 2022 | 25,000 | 2,704 | - | 30.0 | 750,005 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.28 per share. | 01 Nov 2022 | 14,982 | 27,704 | - | 10.3 | 154,015 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 14,982 | 104,951 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 10,018 | 60,110 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 01 Nov 2022 | 10,018 | 12,722 | - | 3.5 | 35,063 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 04 Oct 2022 | 25,000 | 2,704 | - | 30 | 750,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.28 per share. | 04 Oct 2022 | 14,982 | 27,704 | - | 10.3 | 154,015 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2022 | 14,982 | 119,933 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2022 | 10,018 | 70,128 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 04 Oct 2022 | 10,018 | 12,722 | - | 3.5 | 35,063 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.19 per share. | 10 Aug 2022 | 36,141 | 21,563 | - | 40.2 | 1,452,532 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2022 | 29,624 | 80,146 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 10 Aug 2022 | 29,624 | 32,328 | - | 3.5 | 103,684 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.28 per share. | 10 Aug 2022 | 25,376 | 57,704 | - | 10.3 | 260,865 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2022 | 25,376 | 134,915 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.10 per share. | 10 Aug 2022 | 18,859 | 2,704 | - | 41.1 | 775,092 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 05 Aug 2022 | 20,000 | 22,704 | - | 3.5 | 70,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.50 per share. | 05 Aug 2022 | 20,000 | 2,704 | - | 32.5 | 650,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 20,000 | 119,770 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 05 Aug 2022 | 10,000 | 12,704 | - | 3.5 | 35,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.75 per share. | 05 Aug 2022 | 10,000 | 2,704 | - | 37.8 | 377,500 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 10,000 | 109,770 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 20 Jul 2022 | 25,000 | 2,704 | - | 30 | 750,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jul 2022 | 25,000 | 139,770 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 20 Jul 2022 | 25,000 | 27,704 | - | 3.5 | 87,500 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 05 Jul 2022 | 25,000 | 2,704 | - | 30 | 750,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jul 2022 | 25,000 | 165,875 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 05 Jul 2022 | 25,000 | 27,704 | - | 3.5 | 87,500 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jul 2022 | 1,105 | 164,770 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.50 per share. | 05 Jul 2022 | 1,105 | 2,704 | - | 32.5 | 35,913 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 05 Jul 2022 | 1,105 | 3,809 | - | 3.5 | 3,868 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 34.65 per share. | 13 Apr 2022 | 45,000 | 1,980 | - | 34.6 | 1,559,093 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 45,000 | 190,875 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 13 Apr 2022 | 45,000 | 46,980 | - | 3.5 | 157,500 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 29 Mar 2022 | 10,000 | 1,980 | - | 35 | 350,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2022 | 10,000 | 235,875 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 29 Mar 2022 | 10,000 | 11,980 | - | 3.5 | 35,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2022 | 30,000 | 290,875 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 09 Mar 2022 | 30,000 | 31,980 | - | 3.5 | 105,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.50 per share. | 09 Mar 2022 | 20,000 | 11,980 | - | 32.5 | 650,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 09 Mar 2022 | 10,000 | 1,980 | - | 35 | 350,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 02 Mar 2022 | 25,000 | 26,980 | - | 3.5 | 87,500 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2022 | 25,000 | 320,875 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 02 Mar 2022 | 25,000 | 1,980 | - | 30 | 750,000 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 23 Dec 2021 | 5,873 | 7,853 | - | 3.5 | 20,556 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 5,873 | 375,002 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 23 Dec 2021 | 5,873 | 1,980 | - | 35.0 | 205,582 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 4,127 | 370,875 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 23 Dec 2021 | 4,127 | 1,980 | - | 35 | 144,445 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 23 Dec 2021 | 4,127 | 6,107 | - | 3.5 | 14,445 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.50 per share. | 21 Dec 2021 | 7,300 | 1,980 | - | 32.5 | 237,250 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 7,300 | 380,875 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 21 Dec 2021 | 7,300 | 9,280 | - | 3.5 | 25,550 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2021 | 55,000 | 425,875 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 10 Nov 2021 | 55,000 | 55,000 | - | 3.5 | 192,500 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.59 per share. | 10 Nov 2021 | 23,632 | 31,368 | - | 38.6 | 911,945 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.44 per share. | 10 Nov 2021 | 13,140 | 2,063 | - | 41.4 | 544,485 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.41 per share. | 10 Nov 2021 | 10,030 | 15,203 | - | 40.4 | 405,335 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.61 per share. | 10 Nov 2021 | 6,135 | 25,233 | - | 39.6 | 243,004 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 42.37 per share. | 10 Nov 2021 | 2,063 | 0 | - | 42.4 | 87,419 | Common Stock |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 247,678 | 247,678 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdings | John Renger | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2020 | 117,801 | 117,801 | - | - | Stock Option (Right to Buy) |